Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

NCT07342244 NA NOT_YET_RECRUITING

This study aims to evaluate whether an innovative combination therapy (CLL1 CAR-T sequential allogeneic hematopoietic stem cell transplantation) is safe, feasible and effective for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML).

Details

Lead sponsor	Donghua Zhang
Phase	NA
Status	NOT_YET_RECRUITING
Enrolment	18
Start date	Fri Jan 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Dec 20 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• AML
• AML (Acute Myeloid Leukemia)

Interventions

• CLL1 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation

Countries

China